Skip to content

Trial · Interventional

CompletedPhase 3Results postedRegistry data

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Overview

Status
Completed
Phase
Phase 3
Enrollment
187 participants (actual)
Sponsor
ACADIA Pharmaceuticals Inc. · Industry
Design
Randomized · Quadruple masking
Countries
1 country

United States

Start
6 Nov 2019
Primary completion
28 Oct 2021
Completion
28 Oct 2021
First posted
29 Nov 2019
Last update posted
8 Apr 2024
Conditions
Rett Syndrome

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2019202020212022
  1. Ph 3

    Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

    NCT04181723

    6 Nov 2019 to 28 Oct 2021

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome

Interventions

  • TrofinetideDrug
  • PlaceboOther

Arms2

  • Experimental

    Drug - Trofinetide

    Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

  • Placebo comparator

    Placebo

    Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12

    Time frame · Baseline and Week 12

    Registry description

    The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the total score. The total score ranges from 0 to 90 and is calculated as the sum of the item scores. Higher scores mean worse behaviour.

  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 12

    Time frame · 12 Weeks Treatment Duration

    Registry description

    To rate how much the subject's illness has improved or worsened relative to a baseline state, a 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

Secondary outcomes(9)
  1. Change From Baseline to Week 12 in Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist - Social Composite Score (CSBS-DP-IT Social)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    Standardized screening scale for assessing communication and pre-linguistic skills in young children 12-24 months and can be used with older children with developmental delay. The CSBS-DP includes a suite of three separate measures: The Infant-Toddler Checklist, a follow-up Caregiver Questionnaire and a Behavior Sample. In this study only the Infant-Toddler (CSBS-DP-IT) Checklist was used. The CSBS-DP-IT Checklist is a 24-item rating scale and each item is scored using a three-level rating of frequency: "not yet", "sometimes" and "often". The CSBS-DP-IT Social Composite score the range was 0 to 26 and a higher score represented a worse outcome. Three composite scores can be calculated: 1) Social Composite; 2) Speech Composite; 3) Symbolic Composite.

  2. Change From Baseline to Week 12 in Impact of Childhood Neurologic Disability Scale (ICND) Total Score

    Time frame · 12 Weeks Treatment Duration

    Registry description

    The Impact of Childhood Neurologic Disability (ICND) scale evaluates the effect of four conditions or health problems on 11 aspects of a child's or family's life as "A lot", "Some", "A little", "Not at all", or "Does not apply". The four conditions or health problems are 1) inattentiveness, impulsivity, or mood, 2) ability to think and remember, 3) neurologic or physical limitations, and 4) epilepsy. The ICND score the range of 0 to 132 and a higher score represents a worse outcome.

  3. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Hand Function (RTT-HF)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    Clinical assessment of the subject's ability to use their hands for functional purposes (such as reaching for and grasping objects, self-feeding, or drawing). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

  4. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    Clinical assessment of the subject's ability to sit, stand, and ambulate (e.g., walking, running, and climbing stairs). The assessment was made on an 8-point Likert scale (0 to 7), with 0 denoting normal functioning and 7 as the most severe impairment.

  5. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    Clinical assessment of the subject's ability to communicate their choices or preferences, which can include the use of nonverbal means such as eye contact or gestures. The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

  6. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    Clinical assessment of the subject's ability to communicate verbally (e.g. words and phrases). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

  7. Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    A 7 point scale that rates the severity of the subject's illness at the time of assessment, relative to the clinician's experience with subjects who have the same diagnosis. A subject is assessed on severity of illness at the time of rating: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

  8. Change From Baseline to Week 12 in Rett Syndrome Caregiver Burden Inventory (RTT-CBI) Total Score (Items 1-24)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    The Rett Syndrome Caregiver Burden Inventory (RTT-CBI) scale is intended to directly address caregiver burden and indirectly assess the significance of treatment effects on function in the context of activities of daily living. Ratings are on a 5-point Likert scale including: 0-never; 1-rarely; 2-sometimes; 3-frequently and 4-nearly always. As in the original Caregiver Burden Inventory, the RTT-CBI has 24 negatively worded items (items 1 through 24) yielding a total score up to 96. The RTT-CBI the range is 0 to 96 and a higher score represents a worse outcome.

  9. Change From Baseline to Week 12 in Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability Scale (ICND)

    Time frame · 12 Weeks Treatment Duration

    Registry description

    The overall quality of life of the subject is also rated by responding to the following: "Please rate your child's overall 'Quality of Life' on the scale below. Choose the number which you feel is best and circle it." The choices range from 1 ("Poor") to 6 ("Excellent").

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeLeast squares mean· Baseline and Week 12

Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12

GroupValue (score on a scale)Spread
Drug - Trofinetide-4.90.94
Placebo-1.70.90
Primary outcomeLeast squares mean· 12 Weeks Treatment Duration

Clinical Global Impression-Improvement (CGI-I) Score at Week 12

GroupValue (score on a scale)Spread
Drug - Trofinetide3.50.07
Placebo3.80.07
Secondary and other outcome results(6)
Secondary outcomeLeast squares mean· 12 Weeks Treatment Duration

Change From Baseline to Week 12 in Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist - Social Composite Score (CSBS-DP-IT Social)

GroupValue (score on a scale)Spread
Drug - Trofinetide-0.10.26
Placebo-1.10.25
Secondary outcomeLeast squares mean· 12 Weeks Treatment Duration

Change From Baseline to Week 12 in Impact of Childhood Neurologic Disability Scale (ICND) Total Score

GroupValue (score on a scale)Spread
Drug - Trofinetide-6.53.44
Placebo-1.93.14
Secondary outcomeLeast squares mean· 12 Weeks Treatment Duration

Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Hand Function (RTT-HF)

GroupValue (score on a scale)Spread
Drug - Trofinetide-0.10.08
Placebo0.00.07
Secondary outcomeLeast squares mean· 12 Weeks Treatment Duration

Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)

GroupValue (score on a scale)Spread
Drug - Trofinetide-0.20.07
Placebo0.00.07
Secondary outcomeLeast squares mean· 12 Weeks Treatment Duration

Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)

GroupValue (score on a scale)Spread
Drug - Trofinetide-0.40.11
Placebo0.00.10
Secondary outcomeLeast squares mean· 12 Weeks Treatment Duration

Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)

GroupValue (score on a scale)Spread
Drug - Trofinetide0.00.06
Placebo0.00.06

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Drug - TrofinetideTrofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube) Trofinetide: Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks0 / 933 / 9381 / 93
PlaceboTrofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube) Placebo: Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks0 / 943 / 9432 / 94

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies3

Studies that cite this trial.

Studies with results

2 studies on this page

Indexing hint: Clinical trial · 2024

4 results

Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome.

Darwish et al. 2024Advances in therapycited by 3

PMID 38363467PMC10960884DOI 10.1007/s12325-024-02796-yPUB-38363467

Free to read · publisher termsCC BY-NC4 results

Indexing hint: Randomized controlled trial · 2023

4 results

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

Neul et al. 2023Nature medicinecited by 154

PMID 37291210PMC10287558DOI 10.1038/s41591-023-02398-1PUB-37291210

CC BY4 results

More studies

1 study on this page

Indexing hint: Clinical trial · 2022

Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.

Neul et al. 2022Contemporary clinical trialscited by 54

PMID 35149233DOI 10.1016/j.cct.2022.106704PUB-35149233

Full text at the publisher
Publisher page

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedParent H, Ferranti A, Niswender C. Trofinetide: a pioneering treatment for Rett syndrome. Trends Pharmacol Sci. 2023 Oct;44(10):740-741. doi: 10.1016/j.tips.2023.06.008. Epub 2023 Jul 16. PMID 37460385

Eligibility

Who could join, as posted.

Sex
Female
Age
from 5 Years up to 20 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. Female subjects 5 to 20 years of age, inclusive, at Screening 2. Body weight ≥12 kg at Screening 3. Can swallow the study medication provided as a liquid solution or can take it by gastrostomy tube 4. Has classic/typical Rett syndrome (RTT) 5. Has a documented disease-causing mutation in the MECP2 gene 6. Has a stable pattern of seizures, or has had no seizures, within 8 weeks of Screening 7. Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter or must agree to use acceptable methods of contraception. Subject must not be pregnant or breastfeeding. 8. The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments 9. Subject and caregiver(s) must reside at a location to which study drug can be delivered and have been at their present residence for at least 3 months prior to Screening Exclusion Criteria: 1. Has been treated with insulin within 12 weeks of Baseline 2. Has current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or has major surgery planned during the study 3. Has a history of, or current, cerebrovascular disease or brain trauma 4. Has significant, uncorrected visual or uncorrected hearing impairment 5. Has a history of, or current, malignancy 6. Has a known history or symptoms of long QT syndrome Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and condition do not meet all pre-specified entry criteria).

PepBank is a research reference. Talk to a doctor before you use any peptide.